#  1 Introduction

##  1.1 Scope of the document

This document provides a description of the DRIVE dissemination plan defining
a clear strategy in terms of responsibility, timing, dissemination tools and
dissemination channels. The purpose of the plan is to ensure that information
is shared with appropriate audiences on a timely basis and by the most
effective means. The overall objective is indeed to find an effective and
understandable way for informing the scientific community and broader public
on the existence of the project and its future value, and distributing and
sharing information and knowledge gained from the project.

Therefore this document aims to:

  * Develop a common understanding of the objectives of the DRIVE dissemination activities 

  

  * Establish mechanisms for effective and timely communication of the project objectives and its evolution 

  

  * Monitor and evaluate the effects of the activity and modify the dissemination as necessary to improve the effectiveness 

  

  * Identify the target audiences 

  

  * Identify the appropriate and relevant key messages and channels for communicating them to the appropriate target audiences 

  

  * Exploit the results of the project after its lifetime. 

  

##  1.2 Dissemination objectives

The overall objective of the DRIVE dissemination activities is to increase the
visibility and impact of the DRIVE research community at European, national
and local levels by informing the scientific community and the society of the
existence of the project, its emerging results and its future benefits to the
health community in general.

Achieving these objectives will:

  1. Increase awareness about the technical results of the project among the scientific community, providing the ground for appraisal of the results. 

  

  2. Promote the real benefits of the DRIVE outputs on patients suffering from diabetes 

  

  3. Reinforce the future potential penetration of the products within the market 

  

  4. Promote the value of the European Commission’s research investment and the beneficial impact that the project’s results will have for the European community of citizens. 

  

  

The dissemination objectives will be reached by working into simultaneous
directions such as:

  * Dissemination of the scientific and technical results. The main instruments will be the scientific publications at conferences and journals, organization and attendance to workshops, conferences, and trade fairs. Each WP will have specific dissemination activities and WP8 will integrate all of them by using the project website and the social media (Twitter and Facebook) as main vehicles for dissemination. 

  

  * Technology transfer to the industry by establishing synergies with the industrial and clinical communities 

  

  * Training activities to support and strengthen the dissemination objective 

  

  * Patients and citizens panel to facilitate the science-society dialogues on chances, risks and ethical aspects of DRIVE project 

  

##  1.3 Dissemination approach and phases

The DRIVE dissemination strategy is based on progressively increasing
dissemination efforts as project results are obtained, to spread as much as
possible the concept behind the DRIVE project ensuring the favourable
conditions for facilitating the exploitation after the end of project. The
dissemination strategy is intended to optimise the dissemination of project
knowledge and results to companies and organisations, which share an interest
in the scientific results and the applications produced during project
conduction.

The dissemination strategy and timeline is outlined in the table 1:  
  
<table>  
<tr>  
<th>

**Year**

</th>  
<th>

</th>  
<th>

**Objective**

</th>  
<th>

</th>  
<th>

**Methods**

</th> </tr>  
<tr>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>

</td> </tr>  
<tr>  
<td>

**1**

</td>  
<td>





</td>  
<td>

Define a “corporate brand” for the project.

Create awareness on DRIVE project.

</td>  
<td>





</td>  
<td>

Design of a project logo, of a public web site and of dedicated pages in the
main social networks (Linkedin, Twitter and Facebook) and on YouTube

Publication of high quality graphic materials

(leaflets, brochures and posters)

</td> </tr>  
<tr>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>



</td>  
<td>

Attendance to seminars, conferences and congresses.

</td> </tr>  
<tr>  
<td>

**2 and 3**

</td>  
<td>







</td>  
<td>

Dissemination in strategic boards of participants.

Increase awareness and acceptance of the technologies developed

Engage with potential industry and associations.

</td>  
<td>









</td>  
<td>

Attendance to seminars, conferences and congresses.

Aligning events with similar or complementary EU or national projects.

Seminars focused to disseminate project results and application to
stakeholders.

Web site and social network pages enrichment

</td> </tr>  
<tr>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>



</td>  
<td>

Newsletters to potential industries and associations

</td> </tr>  
<tr>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>

</td> </tr>  
<tr>  
<td>

**4**

</td>  
<td>



</td>  
<td>

Solicit first commercial interest for further

development/optimisation of the technologies developed

</td>  
<td>





</td>  
<td>

Attendance to seminars, conferences and congresses

Organisation of seminars focused on business opportunities involving top and
middle managers of industrial organisations

</td> </tr>  
<tr>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>



</td>  
<td>

Preparation of a pre-commercial brochure.

</td> </tr>  
<tr>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>



</td>  
<td>

Newsletter to potential industry associations

</td> </tr>  
<tr>  
<td>

</td>  
<td>



</td>  
<td>

Promote the commercial

exploitation of DRIVE results

</td>  
<td>

</td>  
<td>

</td> </tr>  
<tr>  
<td>

**Beyond 4**

</td>  
<td>





</td>  
<td>

Preparation of a commercial brochure.

Promotion in commercial fairs.

</td> </tr>  
<tr>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>



</td>  
<td>

Newsletter to targeted industry associations.

</td> </tr>  
<tr>  
<td>

</td>  
<td>

</td>  
<td>

</td>  
<td>



</td>  
<td>

Business meetings with top and middle managers of industrial organisations

</td> </tr> </table>

**Table 1: DRIVE’s dissemination strategy and timeline**

The dissemination effort for the project began with the establishment of the
logo of the project, of the project’s web site and dedicated pages on
important social media such as Facebook and Twitter. The members of the
project will also write academic and technical papers and scientific posters,
to be presented at conference and published in leading academic and technical
journals.

#  2 Dissemination strategy

##  2.1 Identification of target stakeholders

In order to create an impact that will last beyond the end of the project by
disseminating the research results to those who could benefit from them, the
Consortium has identified different stakeholders who would be the first to
implement and benefit from its outputs. The following have been selected as
the main group of target stakeholders:

  1. Research and wider scientific community, in particular the one dealing with biomaterials development, diabetes treatment, islet transplantation, stem cells & regenerative medicine, nano-biotechnology 

  

  2. Prospective customer base: regenerative medicine/cell therapy companies, biotechnology companies, diabetes hospitals, clinical centres and Research Institutes, transplant surgeons 

  

  3. Wider community of potential end users: type 1 (and in the future potentially type 2) diabetes patients 

  

  

Due to the diversified target audiences, the communication strategy envisions
tailoring key messages to be transmitted in an appropriate way to the
different target groups focusing on positive achievements of the project and
the benefits they could bring. This requires clear agreement and careful
coordination among all the partners who may act as speakers or information
sources for a particular project or network. Key messages will be defined
taking in mind the potential impact of the project results for a target
audience and the appropriate modes of communication.

The programme will then use a wide range of dissemination channels for
reaching these target audiences, including:

  * Free access to DRIVE public website (target: all groups) 

  

  * Events and exhibitions (main target: groups 1 and 2) 

  

  * Advertisements and notices in specialised journals and newspapers (main target: 

  

groups 1 and 2)

  * Newsletters, leaflets and brochures (target: all groups) 

  

  * Participation at sector-relevant exhibitions and conferences (main target: groups 1 and 2) 

  

  * Participation at EC events (main target: groups 1 and 2) 

  

  * Scientific papers, journal articles, press releases (main target: groups 1 and 2) 

  

  * The display of notices and issue of publicity materials to their public contacts by the partners (target: all groups) 

  

  * Mail-shots (target: all groups) 

  

Patients and citizens panel to facilitate the science-society dialogues on
chances, risks and ethical aspects of DRIVE project (main target: group 3)

##  2.2 Dissemination responsibilities

DRIVE is a project whose outcomes could dramatically impact on the quality of
life of patients suffering from diabetes (in particular from T1D) and
significantly reduce the social costs of this disease at worldwide level.

According to the American Diabetes Association (2013) the total costs of
diagnosed diabetes have risen to $245 billion in 2012 from $174 billion in
2007, when the cost was last examined. This figure represents a 41 percent
increase over a five year period. Most of the cost for diabetes care in the
U.S., 62.4%, is provided by government insurance (including Medicare,
Medicaid, and the military). The rest is paid for by private insurance (34.4%)
or by the uninsured (3.2%).

For this reason the whole Consortium needs to ensure an appropriate and
effective dissemination of non confidential information about DRIVE aims,
preliminary results, and clinical perspectives.

The dissemination activities have been structured in a way to actively involve
all the partners to effectively disseminate project results to the widest
possible audience, in order to create a critical mass of interest around the
project at national, European and worldwide level.

The dissemination partner leader (INNOVA) will work to ensure proper
information dissemination to support the full communication of the project
results. Partners are involved to provide a structured and dynamic approach to
the dissemination of project results.

##  2.3 Dissemination tools

Different dissemination materials will be designed and shaped during the
entire life of the project following the evolution of the project and
according to the different communications needs, and to the various events
typologies and stakeholder groups. In particular:

#  The visual identity (logo) of the project

It represents the first milestone in the dissemination strategy, being the
basis of the project visibility. An attractive and effective graphical
representation helps provide interested parties with the message that the
project delivers. The logo has been designed by a professional graphics
designer to consistently communicate and disseminate the main project concept
of using cells and biomaterials to guarantee the sufficient production of
insulin on behalf of pancreatic islets. The logo is reported in the fig.1:

**Figure 1: logo of the DRIVE project**

#  Templates

Templates for power point presentations have been prepared and made accessible
for all members of the project. The templates are important to give a uniform
image of the project and to begin a visual language that allow to immediately
link to the DRIVE project the presented information.

#  Digital artwork

**High resolution three dimensional images depicting DRIVE’s novel
technologies have been commissioned from a graphic design company specialising
in life sciences. These images will be used in DRIVE dissemination outputs
throughout the project to draw attention to the expected results.**

#  Web site

The DRIVE website (  _www.DRIVE-project.eu_ )  is the main communication tool
to disseminate project results and achievements. The web site will be the main
source of information on the project, on its initiatives (events, conferences,
workshops, etc.) and trainings. The website will contain dissemination items
such as press releases, brochures, newsletters and links to new articles.

#  Poster

Some posters describing DRIVE’s approach and the project’s aims have been
already developed and presented in conferences (e.g. IPITA 2015) and outreach
events (Discover Research Dublin

2015) and have been uploaded to the Content Management System for use by DRIVE
partners. Following the evolution of the project, different typologies of
posters according to different needs will be designed to demonstrate and
disseminate to diverse target audiences the projects objectives and the
achieved results.

#  Brochures

The project brochure will be designed between the 1  st  and 2  nd  year of
implementation to provide general information regarding the Drive project, its
objectives and achievements. It will be designed for a standard paper size, to
allow the interested partners to easily download it from the project website
and print it for their own dissemination purposes.

#  Newsletter

The Consortium will produce periodic newsletters that will highlight key
results and achievements of the project. It will be published on the project
website and distributed via email to a list of stakeholder’s contacts.

#  Publications

DRIVE partners will prepare and submit articles in open access, peer-reviewed
high-level journals, proceeding of conferences as well as in daily newspaper
or in magazines addressing a broad public. The results of the scientific
research work will be submitted for publication to international, peer-
reviewed high-level scientific journals relevant for DRIVE (e.g.
Diabeteologia, Diabetes, Journal of Controlled Release, Nature Materials,
Biomaterials, Tissue Engineering) and, in case, in broad-subject journals (for
information to the scientists and private institutions in other related
fields) following the open access principles.

#  Press release

The press releases aims to attract attention to major project developments and
achievements. An initial press release has been prepared by the Project
Coordinator to generate initial interest in the project by the general public.
During the project life, there will be at least one press release per year
which will focus on the completion of a major milestone rather than general
project progress.

#  Panels (patient and citizen)

The Consortium will organize target panels in order to involve patients and
citizens in a two-way dialogue with scientists and medical doctors. The focus
will be on the social, ethical, cultural, economic and legal aspects of the
diabetes disease treatments underlying the innovation and the effectiveness of
the DRIVE approach. A pilot panel will be held in Dublin, followed by
additional panels in Italy and Germany which will take advantage from the
evaluation of the pilot event.

#  Presentations at external events and conferences

The partners will prepare and deliver papers, communications and lectures at
seminars, relevant conferences and workshops at national and international
level. A list of conferences will be developed through the course of the
project with the aim of increasing visibility and sharing of the achieved
results.

#  Social media: Twitter and Facebook

DRIVE will use social networks such as Linkedin, Twitter and Facebook as
useful dissemination tool and channels. In particular, the project will take
advantage of the well-established LinkedIn connections of each partner and
will create a LinkedIn groups to promote and facilitate a dialogue around the
project activities. The twitter account as well as the Facebook page of the
project have already been created and will be continuously updated with the
forthcoming news and events related to the DRIVE project.

##  2.4 Relationships with other relevant initiatives

The DRIVE project will also continue to link to other relevant international
activities and existing research initiatives in the same field. The partners
will establish links to other European research initiatives related to the
topics of DRIVE where they are currently involved, such as ETPNANOMEDICINE
(RCSI member), the FP7 “NEXT” project (where EXPLORA is one of the main
partners), REDDSTAR (DRIVE clinical collaborators). In addition the project
will create a relationship with the following relevant initiatives:  
  
<table>  
<tr>  
<th>

**Resource**

</th>  
<th>

**Description**

</th> </tr>  
<tr>  
<td>

DIABETES

RESEARCH

INSITITUTE

FONDATION

</td>  
<td>

The Diabetes Research Institute leads the world in  _cure-focused research_ .
As the largest and most comprehensive research center dedicated to curing
diabetes, the DRI is aggressively working to develop a biological cure by
restoring natural insulin production and normalizing blood sugar levels
without imposing other risks.

</td> </tr>  
<tr>  
<td>

JDRF

</td>  
<td>

JDRF is the leading global organization funding type 1 diabetes (T1D)
research. Type 1 diabetes is an autoimmune disease that strikes both children
and adults suddenly. JDRF works every day to change the reality of this
disease for millions of people—and to prevent anyone else from ever knowing
it—by funding research, advocating for government support of research and new
therapies, ensuring new therapies come to market and connecting and engaging
the T1D community.

</td> </tr>  
<tr>  
<td>

EASD

</td>  
<td>

The European Association for the Study of Diabetes (EASD) is based on
individual membership and embraces scientists, physicians, laboratory workers,
nurses and students from all over the world who are interested in diabetes and
related subjects. Members are entitled to vote at the General Assembly, which
is held during the Annual Meeting and are eligible for election to the Council
and to the Executive Committee. Membership also provides the possibility of
attending the Annual Meetings of the Association at a considerably reduced
registration fee. Active members receive monthly the official journal of the
Association, Diabetologia, which publishes articles on clinical and
experimental diabetes and metabolism.

</td> </tr>  
<tr>  
<td>

IDF

</td>  
<td>

IDF Europe is the European chapter of the International Diabetes Federation
(IDF). IDF are a diverse and inclusive multicultural network of national
diabetes associations, representing both people living with diabetes and
healthcare professionals. Through our activities, IDF aim to influence policy,
increase public awareness and encourage health improvement, and promote the
exchange of best practice and high-quality information about diabetes
throughout the European region.

</td> </tr>  
<tr>  
<td>

AMERICAN

DIABETES

ASSOCIATION

</td>  
<td>

American Diabetes Association lead the fight against the deadly consequences
of diabetes and fight for those affected by diabetes.

  * fund research to prevent, cure and manage diabetes. 

  

  * deliver services to hundreds of communities. 

  

  * provide objective and credible information. 

  

  * give voice to those denied their rights because of diabetes. 

  

</td> </tr>  
<tr>  
<td>

HUMEN PROJECT

</td>  
<td>

The HumEn project brings together six leading European stem cell-research
groups and three industrial partners in a coordinated and collaborative effort
aimed at developing glucose-

</td> </tr>  
<tr>  
<td>

**Resource**

</td>  
<td>

**Description**

</td> </tr>  
<tr>  
<td>

</td>  
<td>

responsive, insulin-producing beta cells for future cell-replacement therapy
in diabetes.

</td> </tr>  
<tr>  
<td>

SEMMA

THERAPEUTICS

</td>  
<td>

Semma Therapeutics was founded to develop transformative therapies for
patients who currently depend on insulin injections. Recent work led to the
discovery of a method to generate billions of functional, insulin-producing
beta cells in the laboratory. This breakthrough technology has been
exclusively licensed to Semma Therapeutics for the development of a cell-based
therapy for diabetes. Semma Therapeutics is working to bring this new
therapeutic option to the clinic and improve the lives of patients with
diabetes

</td> </tr>  
<tr>  
<td>

NIDDK

</td>  
<td>

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
conducts, supports, and coordinates research on many of the most serious
diseases affecting public health. The Institute supports clinical research on
the diseases of internal medicine and related subspecialty fields, as well as
many basic science disciplines.

</td> </tr> </table>

##  2.5 Activities to reach the general public

In addition to the more specific audiences the DRIVE project is also committed
to disseminating information about the project and its potential benefits to
the wider general public. In order to achieve this objective a specific
programme of public awareness activities has been developed and this is
presented below.  
  
<table>  
<tr>  
<th>

**Activity**

</th>  
<th>

**Timetable**

</th>  
<th>

**Objectives**

</th>  
<th>

**Expected Impact**

</th> </tr>  
<tr>  
<td>

Press releases to key general press for broad public awareness raising

</td>  
<td>

From

Month 6

</td>  
<td>

Awareness of DRIVE in selected general press publications

</td>  
<td>

Early public awareness raising

</td> </tr>  
<tr>  
<td>

Identification of key possible target audiences for public awareness raising
and suitable channels of communication

</td>  
<td>

From

Month 12

</td>  
<td>

To raise visibility and impact of DRIVE activities and results beyond the
research community

</td>  
<td>

Greater awareness of DRIVE opportunities and benefits across the broadest
possible range of communities

</td> </tr>  
<tr>  
<td>

Development of DRIVE dissemination materials for nonspecialist public
audiences

</td>  
<td>

From

Month 12

</td>  
<td>

To raise visibility and impact of DRIVE activities and results beyond the
research community

</td>  
<td>

Pan-European public awareness of DRIVE and effective handling of enquiries

</td> </tr> </table>  
<table>  
<tr>  
<th>

**Activity**

</th>  
<th>

**Timetable**

</th>  
<th>

**Objectives**

</th>  
<th>

**Expected Impact**

</th> </tr>  
<tr>  
<td>

Organization of patients and citizen panels

</td>  
<td>

From

Month 18

</td>  
<td>

Promote the wider public understanding of the full range of DRIVE benefits as
the project progresses

</td>  
<td>

Increase in awareness and support for building the future user base.

</td> </tr> </table>

#  3 Completed activities

##  3.1 Logo and website

The creation of a project website included agreement and introduction of the
project logo, as described above. A website (www.DRIVE-project.eu) has been
established by INNOVA, with the assistance of all partners and includes public
partner profiles, logo and as work proceeds, the Consortium will supply INNOVA
with relevant images and results suitable for public viewing.

**Figure 2: screenshot of the DRIVE homepage**

**Figure 3: screenshot of the DRIVE “the challenge” section**

**Figure 4: screenshot of the DRIVE “our excellence” section**

##  3.2 Social media dedicated pages

The twitter account as well as the Facebook page of DRIVE project have been
already created and will be continuously updated with the forthcoming news and
events related to the DRIVE project.

**Figure 5: the twitter account of DRIVE (@DRIVE4diabetes)**

**Figure 6: the Facebook page of DRIVE**

** ( _https://www.facebook.com/DRIVEforDiabetes_ )  **

##  3.3 DRIVE Outreach Events

On the day of the 15  th  \- 19  th  November 2015, DRIVE researchers took
part in IPITA joint conference in Melbourne  ( _http://melbourne2015.org/_ )
, one of the most important congresses in the world on pancreas and islets
transplantation. Garry Duffy (RCSI, DRIVE's Coordinator) and Eoin O'Cearbhaill
(UCD, DRIVE PI) submitted on behalf of DRIVE at IPITA joint conference in
Melbourne. DRIVE's Prof Paul Johnson (Oxford Consortium for Islet Transplant)
was there to give a number of talks on his group’s latest islet
transplantation research.

**Figure 7: DRIVE’s coordinator, Garry Duffy (RCSI), presenting DRIVE at IPITA
joint conference in Melbourne, November 2015**

On the evening of the 25  th  September 2015, DRIVE researchers have taken
part in Discover Research Dublin 2015  ( _www.discoverresearchdublin.com_ )  ,
an interactive night of free public engagement events on wide variety of
research themes. The initiative was funded by the European Commission's
Research and Innovation Framework Programme H2020 (2014-2020) by the Marie
Skłodowska-Curie actions and was hosted by Trinity College Dublin (TCD).

**Figure 8: DRIVE researchers meeting the public at Discover Research Dublin,
25th**

**September 2015**

**Figure 9: DRIVE researchers meeting the public at Discover Research Dublin,
25th**

**September 2015**

**Figure 10: DRIVE researchers meeting the public at Discover Research Dublin,
25th September 2015**

On 21st June 2015 Dr. Liam Burke (DRIVE’s program manager) gave the support of
the DRIVE Consortium to a fundraising event  ( _Lap the Lake_ )  of Diabetes
Ireland, the only national charity in Ireland dedicated to helping people with
diabetes.

**Figure 11: DRIVE’s program manager Liam Burke (RCSI) at the Lap the Lake
charity run organised by Diabetes Ireland**

#  4 Future Plans

The already planned future dissemination activities for DRIVE are set out in
the following table. In particular the project will possibly target the
following international initiatives:  
  
<table>  
<tr>  
<th>

**Event name**

</th>  
<th>

**Date & Place **

</th>  
<th>

**Type of**

**Event***

</th>  
<th>

**Short description and website (if available)**

</th> </tr>  
<tr>  
<td>

Controlled Release

Society (CRS)

Annual Meeting

</td>  
<td>

Seattle,

Washington,

USA

July 17-20

2016

</td>  
<td>

CO

</td>  
<td>

With the theme "Advancing Delivery Science & Technology Innovation," this high
quality CRS event will bring together an international audience of nearly
1,450, from over 50 countries. A dynamic program committee headed by Kinam
Park, promises attendees cutting-edge research, innovation, and collaboration.

_http://www.controlledreleasesociety.org/meetings/annual/Pages/_
_default.aspx_

</td> </tr>  
<tr>  
<td>

European Chapter Meeting of the

Tissue Engineering and Regenerative

Medicine

International

Society (TERMIS)

2016

</td>  
<td>

Uppsala,

Sweden, June 28th-July 1st

2016

</td>  
<td>

CO

</td>  
<td>

The theme of the 2016 TERMIS-EU conference in Uppsala, Sweden is "Towards
Future Regenerative Therapies". The goal of the conference is to bring
together the leading experts within the tissue engineering and regenerative
medicine community to present and discuss their latest scientific and clinical
developments. These last years of research, and especially the increased
collaborations between various specialties, have led to tangible improvements
that are now starting to benefit patients. This meeting will not only serve as
an important teaching platform, but will also give young scientists the
opportunity to present innovative studies. The human networking aspect of such
a meeting and encouraging the exchange of ideas and knowledge are equally
important, not only between

scientists, but also with our industrial partners to allow translation to many
patients.  _http://www.termis.org/eu2016/_

</td> </tr>  
<tr>  
<td>

52nd European

Association for the

Study of Diabetes

(EASD) Annual

Meeting

</td>  
<td>

Munich,

Germany, 1216  th  Sept 2016

</td>  
<td>

CO

</td>  
<td>

The EASD Annual Meeting has become the world´s leading international forum for
diabetes research and medicine. It is held in a different European city each
year.

During the Scientific Programme all relevant companies involved in diabetes
care and treatment present tomorrow´s products and services at the industry
exhibition area.

For the first time at this year's EASD, not only Industry Symposia, on Monday
12 September but also the new Evening Symposia on Wednesday, 14 September and
Thursday, 15 September offer excellent opportunities to gain insights into the
latest innovations and cutting-edge products in the field of diabetes.

_http://www.easd-industry.com/_

</td> </tr>  
<tr>  
<td>

**Event name**

</td>  
<td>

**Date & Place **

</td>  
<td>

**Type of**

**Event***

</td>  
<td>

**Short description and website (if available)**

</td> </tr>  
<tr>  
<td>

Discover Research

Dublin 2016

</td>  
<td>

Dublin, Ireland

30th

September

2016

</td>  
<td>

EX

</td>  
<td>

Discover Research Dublin is an event funded by the EU under the Horizon 2020
framework as part of European Researchers Night. This takes place on the last
Friday of every September.

DRIVE researchers participated in DRD 2015 where they interacted with the
general public giving, talks, demos and chats. The public will again have the
chance to meet DRIVE researchers and to hear about the progress of the
project. The aim of the event is outreach: to demonstrate that research isn’t
an ivory tower pursuit, and it has real impacts in everyone’s daily lives.
_http://discoverresearchdublin.com/_

</td> </tr>  
<tr>  
<td>

28th European

Society for

Biomaterials

Annual Congress

</td>  
<td>

Athens,

Greece, 4-8th

September

2017

</td>  
<td>

CO

</td>  
<td>

The European Society for Biomaterials is a non-profit organization at the
forefront of the scientific community determined to tackle unmet clinical
needs by means of advanced materials for medical devices and regenerative
medicine.

The annual congress is a place where scientists, clinicians, industrials and
regulatory affair experts can network to maximise R&D and commercial
opportunities to the benefit of patients. Our interactive website favours
social networking and is a show case for the “innovation” created by our
members.

_http://www.esbiomaterials.eu/Cms/Events_

</td> </tr>  
<tr>  
<td>

16th World

Congress of the

International

Pancreas and Islet Transplant

Association (IPITA)

</td>  
<td>

Place TBC

2017

</td>  
<td>

CO

</td>  
<td>

This is a highly specialised bi-annual conference that brings together leading
academic, clinical and industrial stakeholders in the field of pancreatic
islet transplant. The DRIVE Project was introduced at the recent conference in
2015, but by 2017 plan to have some exciting results to share with the islet
transplant community. 2015 conference:  _http://melbourne2015.org/_

</td> </tr>  
<tr>  
<td>

DRIVE Citizens and

Patients Panels

</td>  
<td>

Ireland, Italy

and Germany,

2016-2017

</td>  
<td>

CO

</td>  
<td>

The use of stem cells and nanotechnology has evoked a public debate about
their ethical dimension. In order to link DRIVE to society through science-
society dialogues on chances, risks and ethical aspects of DRIVE, **patients
and citizen panels will be organised in the framework of WP8** to discuss
these issues with their potential benefits and risks. This activity is
expected to contribute to overcome the classical one-way communication with
scientists in the role of experts providing information and public and the
role of lay-people receiving information. Engaging in a two-way dialogue
between scientists and patients/public is DRIVE’s goal. In this dialogue, both
scientists and non-scientists learn from each other. In addition, politics,
administrative and industrial bodies will benefit from the participants
assessments as their judgments and associations point out the level of
acceptability for decision makers.

</td> </tr> </table>

*CO: conference; EX: Exhibition 

#  5 Data Management Plan description

The data management plan concerns the datasets generated by the project with
the respect to four key attributes: i) a description of the datasets; ii) a
description of the standards and metadata associated with these datasets; iii)
the method that will be employed for sharing these datasets; and iv) a plan
for the long term archiving of these data.

This Data Management plan aims at providing a timely insight into facilities
and expertise necessary for data management both during and after the DRIVE
research, to be used by all DRIVE researchers and their environment.

Long term archiving of the acquired datasets is very important both in terms
of visibility after the end of the project, as well as for a greater
proliferation in the research community.

##  5.1 Data set

Results generated by the participants during the course of and as a result of
the DRIVE project will be owned by the participant(s) generating them and will
be made available to all beneficiaries that will ensure their confidentiality,
as foreseen in the DRIVE Consortium Agreement and in the Grant Agreement
signed with the EC, for non-commercial use and only during the project. When a
result will be generated jointly it will be jointly owned (unless the
participants concerned agree on a different solution ahead of invention).

An internal content management system (CMS, DRIVE deliverable 1.1) has been
developed by Innova. The access is allowed to project partners only through
personalised login data and it will be used as a secure system to share
confidential data between DRIVE partners.

##  5.2 Standard and metadata

The partners of DRIVE will assume the compromise to make their best effort to
deposit at the same time the research data needed to validate the results
presented in the deposited scientific publications, into an open access online
repository.

**In compliance with Horizon 2020 rules, the results obtained will be
published only after proper IP protection with the written approval of all
partners who have contributed to the achievement of the results.**

We intend to share our dataset in a publicly accessible disciplinary
repository using descriptive metadata as required/provided by that repository
called ‘e-publications@RCSI’. This ensures the availability, dissemination and
preservation of publications open to all. The repository, managed by RCSI
Library, provides a robust and stable archive of RCSI’s scholarly output. All
archive content is freely available on the web and it is discoverable by a
wide range of search engines and it optimizes worldwide access to published
work.

##  5.3 Data sharing

Any publishable scientific and technical result arising from the scope of
DRIVE will be subject to a double Open Access strategy. Initially, the
published article or the final peer reviewed manuscript will be archived by
depositing in an online repository after or alongside its publication
according to the requirements of “green” open access. However, if the embargo
period requested by the scientific publisher surpasses the 6 months limit
settled by the EC, the publication will be moved to “gold” open access
granting its immediate open access by the scientific publisher.

##  5.4 Archiving and preservation

To ensure a long term access to data and results obtained by the DRIVE
consortium, the internal content management system (CMS) of DRIVE mentioned in
the section 51 will be used. A “guide for private documents management” has
been set up by Innova and distributed to all partners.